FR3000492B1 - Nouveaux derives azaindole en tant qu'inhibiteurs multikinases - Google Patents
Nouveaux derives azaindole en tant qu'inhibiteurs multikinasesInfo
- Publication number
- FR3000492B1 FR3000492B1 FR1262931A FR1262931A FR3000492B1 FR 3000492 B1 FR3000492 B1 FR 3000492B1 FR 1262931 A FR1262931 A FR 1262931A FR 1262931 A FR1262931 A FR 1262931A FR 3000492 B1 FR3000492 B1 FR 3000492B1
- Authority
- FR
- France
- Prior art keywords
- azaindole derivatives
- multikinase inhibitors
- novel azaindole
- novel
- multikinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1262931A FR3000492B1 (fr) | 2012-12-28 | 2012-12-28 | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
AU2013369242A AU2013369242A1 (en) | 2012-12-28 | 2013-12-30 | Azaindole derivatives as multi kinase inhibitors |
PCT/EP2013/078139 WO2014102377A1 (fr) | 2012-12-28 | 2013-12-30 | Dérivés aza-indoliques utilisés comme inhibiteurs de multiples kinases |
JP2015550096A JP2016507508A (ja) | 2012-12-28 | 2013-12-30 | マルチキナーゼ阻害薬としてのアザインドール誘導体 |
US14/655,609 US9550772B2 (en) | 2012-12-28 | 2013-12-30 | Azaindole derivatives as multi kinase inhibitors |
EP13815532.0A EP2938614A1 (fr) | 2012-12-28 | 2013-12-30 | Dérivés aza-indoliques utilisés comme inhibiteurs de multiples kinases |
CA2896818A CA2896818A1 (fr) | 2012-12-28 | 2013-12-30 | Derives aza-indoliques utilises comme inhibiteurs de multiples kinases |
KR1020157020247A KR20150108846A (ko) | 2012-12-28 | 2013-12-30 | 멀티 키나아제 억제제로서의 아자인돌 유도체 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1262931A FR3000492B1 (fr) | 2012-12-28 | 2012-12-28 | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3000492A1 FR3000492A1 (fr) | 2014-07-04 |
FR3000492B1 true FR3000492B1 (fr) | 2015-09-11 |
Family
ID=47989195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1262931A Expired - Fee Related FR3000492B1 (fr) | 2012-12-28 | 2012-12-28 | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
Country Status (8)
Country | Link |
---|---|
US (1) | US9550772B2 (fr) |
EP (1) | EP2938614A1 (fr) |
JP (1) | JP2016507508A (fr) |
KR (1) | KR20150108846A (fr) |
AU (1) | AU2013369242A1 (fr) |
CA (1) | CA2896818A1 (fr) |
FR (1) | FR3000492B1 (fr) |
WO (1) | WO2014102377A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2594742C2 (ru) | 2010-05-20 | 2016-08-20 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
FR3000494B1 (fr) * | 2012-12-28 | 2015-08-21 | Oribase Pharma | Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases |
MX2018000577A (es) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa. |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
CA3150433A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
FI4084778T3 (fi) | 2019-12-30 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi |
CA3163051A1 (fr) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Compositions de 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophenyl)-3-phenyluree |
MX2023003996A (es) * | 2020-10-05 | 2023-06-15 | Enliven Inc | Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl. |
JP2023546352A (ja) | 2020-10-05 | 2023-11-02 | エンライブン インコーポレイテッド | Bcr-ablチロシンキナーゼの阻害のための5-及び6-アザインドール化合物 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE499372T1 (de) * | 2005-07-29 | 2011-03-15 | Hoffmann La Roche | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel |
BRPI0716477A2 (pt) * | 2006-09-06 | 2014-03-18 | Hoffmann La Roche | Derivados heteroarila como inibidores de quinase protéica |
CN101600714B (zh) * | 2006-11-10 | 2013-08-21 | 百时美施贵宝公司 | 吡咯并吡啶激酶抑制剂 |
WO2008144253A1 (fr) * | 2007-05-14 | 2008-11-27 | Irm Llc | Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci |
AU2008276063B2 (en) * | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2265608A2 (fr) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | Composés inhibiteurs de kinases raf et procédés d utilisation |
FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
-
2012
- 2012-12-28 FR FR1262931A patent/FR3000492B1/fr not_active Expired - Fee Related
-
2013
- 2013-12-30 AU AU2013369242A patent/AU2013369242A1/en not_active Abandoned
- 2013-12-30 KR KR1020157020247A patent/KR20150108846A/ko not_active Application Discontinuation
- 2013-12-30 JP JP2015550096A patent/JP2016507508A/ja active Pending
- 2013-12-30 CA CA2896818A patent/CA2896818A1/fr not_active Abandoned
- 2013-12-30 EP EP13815532.0A patent/EP2938614A1/fr not_active Withdrawn
- 2013-12-30 US US14/655,609 patent/US9550772B2/en not_active Expired - Fee Related
- 2013-12-30 WO PCT/EP2013/078139 patent/WO2014102377A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20150353539A1 (en) | 2015-12-10 |
CA2896818A1 (fr) | 2014-07-03 |
AU2013369242A1 (en) | 2015-07-16 |
KR20150108846A (ko) | 2015-09-30 |
FR3000492A1 (fr) | 2014-07-04 |
EP2938614A1 (fr) | 2015-11-04 |
US9550772B2 (en) | 2017-01-24 |
WO2014102377A1 (fr) | 2014-07-03 |
JP2016507508A (ja) | 2016-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR3000492B1 (fr) | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases | |
FR22C1047I2 (fr) | Derives de benzimidazole-proline | |
SMT201700065B (it) | Derivato piridonico | |
SMT201600108B (it) | Derivato di pirazochinolina come inibitori di pde9 | |
SMT201500037B (it) | Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti | |
FR3000494B1 (fr) | Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases | |
SMT201500270B (it) | Derivati di pirrolotriazinone come inibitori di pi3k | |
DK2785695T3 (da) | Nye bicykliske dihydroisoquinolin-1-on-derivater | |
DK2755963T3 (da) | Nye dihydroquinolin-2-on-derivater | |
DK2850067T3 (da) | Carboxylsyreforbindelser | |
SMT201700108B (it) | Derivati delle mostarde azotate | |
BR112014000445A2 (pt) | usos de inibidores de hsp90 marcados | |
AR092198A1 (es) | Derivados de pirazolopirimidinas | |
BR112014028334A2 (pt) | derivados dipeptídicos de lisina ácido glutâmico. | |
DK2900645T3 (da) | Herbicidt aktive 3-phenylisoxazolinderivater | |
FI9152U1 (fi) | Säädettävä tolppakiinnitin | |
CO6940426A2 (es) | Formulaciones farmacéuticas | |
BR112014000015A2 (pt) | formulação | |
DK2836494T3 (da) | Nye alkyleringsmidler | |
FR2973378B1 (fr) | Derives d'acide hydroxybisphosphonique bifonctionnels | |
DK2877155T3 (da) | Opioidformuleringer | |
DK2851075T3 (da) | Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat | |
CO6852074A2 (es) | Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida | |
ES1078038Y (es) | Aposito ocular | |
DK2854789T3 (da) | Genotype- eller fænotype-baserede lægemiddelformuleringer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
ST | Notification of lapse |
Effective date: 20180831 |